Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
amplimed.com

See what CB Insights has to offer

Total Raised

$41.49M

Investors Count

7

Deal Terms

4

AmpliMed Funding, AmpliMed Valuation & AmpliMed Revenue

6 Fundings

AmpliMed's latest funding round was a Series D for $3.9M on August 10, 2009.

AmpliMed's valuation in November 2006 was $64.02M.

AmpliMed's latest post-money valuation is from August 2009.

Sign up for a free 30-day trial to see AmpliMed's valuations in August 2009 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/10/2009

Series D

$3.9M

$99M

$0.00B

((9.99x))

FY 1234

1/18/2009

Grant

$99M

$0.00B

((9.99x))

FY 1234

10

1/11/2008

Series C

$99M

$0.00B

((9.99x))

FY 1234

10

11/21/2006

Series B

$99M

$64.02M

$0.00B

((9.99x))

FY 1234

10

11/21/2006

Series B - II

$99M

$0.00B

((9.99x))

FY 1234

10

Date

8/10/2009

1/18/2009

1/11/2008

11/21/2006

11/21/2006

Round

Series D

Grant

Series C

Series B

Series B - II

Amount

$3.9M

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$64.02M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

10

10

10

10

AmpliMed Deal Terms

4 Deal Terms

AmpliMed's deal structure is available for 4 funding rounds, including their Series D from August 10, 2009.

Round

Series D

Series C

Series B

Series A

Funding Date

$99M

$99M

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

AmpliMed Investors

7 Investors

AmpliMed has 7 investors. Solstice Capital invested in AmpliMed's Series A funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

5/20/2004

8/10/2009

5
Series D, Series C (2008), Series B (2006), Series B - II (2006), Series A (2004)

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Iowa

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Asset/Investment Management

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Massachusetts

First funding

5/20/2004

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

8/10/2009

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

5
Series D, Series C (2008), Series B (2006), Series B - II (2006), Series A (2004)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Venture Capital

Venture Capital

Asset/Investment Management

Venture Capital

Venture Capital

Location

Massachusetts

Iowa

California

New York

Massachusetts

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.